Abstract
Objectives: Despite considerable interest in the Nuclear factor-erythroid 2-related factor 2 (Nrf2)/Kelch-like ECH-associated protein-1 (Keap1), p16 and epithelial cadherin (E-cadherin) activation in carcinoma progression, contradictory results regarding association of Nrf2/Keap1/E-cadherin and p16 expression with clinico-pathological features and prognosis have been reported. The predictive value of these markers in ovarian carcinoma is unknown. Methods/Materials: In this retrospective study, 108 cases were evaluated immunohistochemically with antibodies to Nrf2, Keap1, estrogen receptor (ER), p16 and E-cadherin. The results were compared with histological and clinical data, disease-free survival (DFS) and overall survival (OS). Results: A cohort of 108 ovarian carcinomas (47 serous, 23 mucinous, 13 endometrioid and 25 clear cell), including 68 FIGO stage I-II cases and 40 FIGO stage III-IV cases was studied. The age of patients (P=0.005), FIGO stage (P
| Original language | English |
|---|---|
| Pages (from-to) | 5642-5649 |
| Number of pages | 8 |
| Journal | International Journal of Clinical and Experimental Pathology |
| Volume | 8 |
| Issue number | 5 |
| Publication status | Published - 2015 |
Keywords
- E-Cadherin
- Keap1
- Nrf2
- Ovarian cancer
- P16
ASJC Scopus subject areas
- Pathology and Forensic Medicine
- Histology
